

Immunoserologic Pepsin Detection in The Saliva as a Non-Invasive Rapid Diagnostic Test for Laryngopharyngeal Reflux

Emre Ocak, Gözde Kubat, İrfan Yorulmaz

Department of Otolaryngology-Head and Neck Surgery, Ankara University Faculty of Medicine, Ankara, Turkey

Background: The most common tool for the diagnosis of laryngopharyngeal reflux (LPR) is still 24-hours esophageal pH monitoring; there is lack of non-invasive, less expensive and accurate diagnostic tools for this frequent disease.

Aims: To evaluate the accuracy of immunoserologic pepsin detection in the saliva for the diagnosis of LPR.

Study Design: Cross-sectional study.

Methods: A two channeled 24-hour esophageal pH monitoring catheter was placed in patients with a suspicion of LPR. During the 24-hour period, each patient gave one sample of sputum for the immunoserologic pepsin detection test. Pathologic gastroesophageal reflux (GER) findings, LPR findings, pH score in the proximal and distal probes when the sputum sample was given were recorded. The sensitivity, specificity, positive and negative predictive values of the pepsin detection test were analyzed and compared to pH monitoring scores.

Results: The study group consisted of 20 patients who

met the criteria. A positive pepsin detection test was elicited from 6 patients. The sensitivity and specificity of the pepsin detection test was 33% and 100%, respectively. A positive predictive value of 100% was recorded. When the pH results of the pepsin positive patients (PPP) and the rest of the study group in the proximal probe at the sample time were compared, the PPP had an apparent acidic pH value compared to the pepsin negative patients (pH: 3.26 for the PPP, pH: 6.81 for the pepsin negative patients).

Conclusion: Pepsin detection in the saliva is a recent method and becoming increasingly popular. Because of the benefits and ease of application, a positive salivary pepsin test in a patient suspected of having LPR can be a cost effective, accurate and alternative diagnostic method. Increasing the daily number of sputum samples may increase the sensitivity of the test.

Keywords: Diagnosis, pepsin, reflux, saliva

Gastroesophageal reflux (GER) refers to the backflow of stomach contents into the esophagus, while the term laryngopharyngeal reflux (LPR) means the backflow of stomach contents into the laryngopharynx according to the position statement of the Committee on Speech, Voice, and Swallowing Disorders of the American Academy of Otolaryngology-Head and Neck Surgery (1). Gastroesophageal reflux disease

(GERD) is a term referring to the clinical symptoms, which is caused by advanced GER. GERD is defined as “a condition that develops when the reflux of stomach contents causes troublesome symptoms and/or complications” in the Montreal Classification (2).

Laryngopharyngeal reflux differs from GERD in many ways, such as symptomatology, treatment modalities and

This study was presented as an oral presentation at the 35th National Meeting of Turkish Otolaryngology Head and Neck Surgery, 2-6 November, 2013, Antalya, Turkey.

Address for Correspondence: Dr. Emre Ocak, Department of Otolaryngology-Head and Neck Surgery, Ankara University Faculty of Medicine, Ankara, Turkey

Phone: +90 535 935 33 94 e-mail: dremreocak@gmail.com

Received: 24.09.2014 Accepted: 27.11.2014 • DOI: 10.5152/balkanmedj.2015.15824

Available at www.balkanmedicaljournal.org

Cite this article as:

Ocak E, Kubat G, Yorulmaz İ. Immunoserologic pepsin detection in the saliva as a non-invasive rapid diagnostic test for laryngopharyngeal reflux. *Balkan Med J* 2015;32:46-50.



TABLE 1. Reflux symptom index

Finding within the last month, how did the following problems affect you?	0 = No Problem 5 = Severe Problem					
	0	1	2	3	4	5
1. Hoarseness or a problem with your voice	0	1	2	3	4	5
2. Clearing your throat	0	1	2	3	4	5
3. Excess throat mucus or postnasal drip	0	1	2	3	4	5
4. Difficulty swallowing food, liquids or pills	0	1	2	3	4	5
5. Coughing after you ate or after lying down	0	1	2	3	4	5
6. Breathing difficulties or choking episodes	0	1	2	3	4	5
7. Troublesome or annoying cough	0	1	2	3	4	5
8. Sensations of something sticking in your throat or a lump in your throat	0	1	2	3	4	5
9. Heartburn, chest pain, indigestion or stomach acid coming up	0	1	2	3	4	5
Total						

TABLE 2. Reflux finding score

Findings	Score
Subglottic edema	0 = Absent, 2 = Present
Ventricular erythema/ hyperemia	0 = None, 2 = Partial, 3 = Complete
Vocal fold edema	0 = None, 2 = Mild, 3 = Severe, 4 = Obstructive
Diffuse laryngeal edema	0 = None, 2 = Mild, 3 = Severe, 4 = Obstructive
Posterior commissure hypertrophy	0 = None, 2 = Mild, 3 = Severe, 4 = Obstructive
Granuloma/granulation of tissue	0 = Absent, 2 = Present
Thick endolaryngeal mucus	0 = Absent, 2 = Present

pathophysiology. Most of the LPR patients do not have heartburn, which is the major symptom of esophagitis (3, 4). The incidence of heartburn in patients with LPR is said to be less than 40% and the incidence of esophagitis is 25% according to previous studies (5). The primary pathophysiologic mechanism of GERD is the lower esophageal dysfunction, whereas the primary defect in LPR is believed to be upper esophageal dysfunction.

The main elements for the diagnosis of LPR are symptomatology and laryngeal findings. Ambulatory 24-hour double probe pH monitoring is the most widely used tool for the diagnosis (6, 7). However, pH monitoring has some disadvantages, such as being an invasive, expensive and difficult to apply method. Therefore, more specific, non-invasive and cost effective diagnostic methods are needed for the diagnosis of LPR.

At this point, pepsin, as a potential factor for damage to the mucosal tissues, draws the attention of clinicians. Laryngeal mucosa is resistant to acidic material above pH 4. However, there are some studies showing that the presence of pepsin can damage the laryngeal tissue, even in mild acidic or alkaline environments (8).

Pepsin can be found in many different tissue samples such as laryngeal mucosa, paranasal sinus mucosa, saliva, middle ear effusion, tracheal secretions and bronchoalveolar lavage fluid (9-11). It is a large molecule; therefore, it can be easily detected after gastric reflux. These features make pepsin a good diagnostic marker for LPR.

MATERIAL AND METHODS

Study design and patient population

Patients who had at least one LPR symptom, whose reflux symptom index (RSI) was above 15 and reflux finding score (RFS) was above 3 were enrolled in the study (Table 1-2) (12, 13). Exclusion criteria were: psychiatric disorders with cooperation disability, previous laryngeal surgery history, any kind of nasal, paranasal, pharyngeal, laryngeal or pulmonary disease which can mimic LPR symptoms and patients who had taken proton pump inhibitors in the last 1 month.

Signed informed consent was obtained from all participants before the study. A double channelled 24-hour esophageal pH monitoring catheter (MMS USA Inc., Dover, USA) with an interprobe distance of 15 cm was placed in every patient. The distal probe was placed 5 cm above the lower esophageal sphincter. During the 24-hour monitoring period, each patient gave one sample of sputum for the pepsin detection test (Peptest, RD Biomed Ltd, Hull, UK) when they had the worst symptoms.

Pathologic GER findings (percentage of time pH<4 in distal probe over 5%), LPR findings (presence of a single attack of pH<4 in the proximal probe), pH score in the proximal and distal probes when the sputum sample was given were recorded. The sensitivity, specificity, positive and negative predictive values of the pepsin detection test were analyzed and compared to pH monitoring scores statistically. Ambulatory pH monitoring and pepsin detection test analysis were double-blinded by separate researchers.



FIG. 1. Pepsin detection kit

The study was performed in accordance with the Declaration of Helsinki, Good Clinical Practice and applicable regulatory requirements. The Ankara University Ethics Committee (EC) approved this study (EC 16-534-12).

Immunoserologic pepsin analysis

Saliva samples were collected in 30 mL standard tubes containing citric acid to preserve the action of any pepsin present for each patient. Immunoserologic pepsin analysis was performed by an investigator who was blinded to the clinical data. The collection tube was centrifuged at 4000 rpm for 5 minutes. After centrifugation, an automated micropipette was used to collect 80 μ L from the supernatant layer of the centrifuged saliva sample. Afterwards, this 80 μ L sample was transferred to another microtube containing 240 μ L of migration buffer solution. After mixing the sample with a vortex mixer for 10 seconds, a dual bulb pipette was used to draw up the 80 μ L of the prepared sample to the pepsin detecting device (RD Biomed Ltd, Hull, UK). The device contains two pepsin monoclonal antibodies to identify the presence of pepsin in the saliva (Figure 1). After placing the sample in the tank, as shown in Figure 1, a blue line appeared in the control panel (letter C) confirming that the test was working correctly. Subsequent to the blue line in the control panel, a second blue line appeared in the test panel (letter T) between 5 and 15 minutes, stating that the sample contained pepsin. The test has the ability to detect pepsin down to 16 ng/mL (14).

RESULTS

The study group consisted of 20 patients (range 18-61 years old) who met the criteria. There were 12 female and 8 male patients. The mean RSI was 22.1 and the mean RFS was 8.1. A positive pepsin detection test was elicited from 6 patients. The major symptom at sampling time was heartburn in 35%, coughing in 30%, sore throat in 25% and regurgitation in 10% of the patients. Ninety percent of the patients had at least one LPR attack (pH<4 in the proximal probe). The mean pH value was 6.38 in the proximal probe and 4.32 in the distal probe at the sample time. Pathologic GER was recorded in 90% of the study group (percentage of time pH<4 in distal probe over

TABLE 3. Patients with pathologic gastroesophageal reflux

Peptest result	pH<4 in the distal probe	
	<5%	>5%
Positive	0	6
Negative	2	12

TABLE 4. pH results in the proximal probe at the sample time

Peptest result	Mean pH value at the sample time	
	Distal probe	Proximal probe
Positive	5.38	3.26
Negative	4.77	6.81

5%). All of the pepsin positive patients (PPP) were within this pathologic GER group (Table 3).

According to our test results, the sensitivity and specificity of the pepsin detection test for GER was 33% and 100%, respectively. The positive predictive value was 100%, while the negative predictive value was 14.2%. Among the PPP, pH<4 in 66% of the distal probe and 33% of the proximal probe at the sampling time. When the pH results of the PPP and the rest of the study group in the proximal probe at the sample time were compared; PPP had an apparent acidic pH value than the pepsin negative patients (pH: 3.26 for the PPP, pH: 6.81 for the pepsin negative patients, Table 4).

DISCUSSION

Laryngopharyngeal reflux is a frequent but mostly misdiagnosed disease in otolaryngology practice. As our knowledge about the pathophysiology of GER and LPR increases, additional patients with nonspecific symptoms will be treated in the correct way. LPR is the underlying factor of many diseases such as pneumonia, rhinosinusitis, asthma, laryngeal cancer and many benign vocal fold lesions (15).

The diagnosis of LPR is challenging because of the atypical symptoms. Currently, 24-hour double probe pH monitoring is the most common tool for the diagnosis of LPR (16). However, the false negative results obtained via pH monitoring is within the range of 15 to 30% (17). pH monitoring is an invasive and expensive method which may be difficult to use in practice (18, 19). Knight et al. (15) reported that approximately 12% of patients do not tolerate this test. In addition, dietary modifications can lead to false negative pH study results and non-acidic reflux (pH \geq 4) cannot be detected by pH monitoring. Another difficulty of pH monitoring is locating the probes in the right position. Postma et al. (20) reported that if the proximal probe is situated higher in the hypopharynx, the sensor would not contact the mucosa, which would cause erroneous results. Multichannel intraluminal impedance, a more recent tool, is a sensitive method but also carries most

of the disadvantages of pH monitoring. These handicaps create the need for a less invasive, cost effective and sensitive diagnostic test (21).

The gastric enzyme pepsin is a member of the family of aspartic proteins, synthesized by the chief cells of the gastric fundus epithelium (22). Pepsin exhibits maximal activity at pH 2.0 and is inactive at pH 6.5 and above. However, pepsin is not fully denatured or irreversibly inactivated until pH 8.0 (23). Pepsin plays the major role in the formation of gastroesophageal reflux and related diseases (24). Acidic reflux material can reach into the esophageal, oropharyngeal and tracheal mucosa. Gastric contents include pepsin but not acid in every reflux episode; regarding this, several studies show that acid does not damage the mucosa by itself. These studies state that pepsin plays the key role in mucosal injury, which can explain the mechanism of injury in the laryngeal mucosa in non-acidic reflux (25). Moreover, laryngeal epithelium has been shown to be more sensitive to the damage caused by pepsin than esophageal epithelium.

In a study by Yuksel et al. (14) *in vitro* bench testing was conducted on 52 gastric juice and 54 sterile water samples to assess test sensitivity and specificity. The pepsin detecting test operating characteristics analysis of *in vitro* samples found an assay sensitivity and specificity of 87%, a positive predictive value of 85% and a negative predictive value of 68%. An immunoserologic test was used similar to the latter study. Another study reports a sensitivity of 89% and a specificity of 68% in a salivary pepsin western blot analysis (26). Other relevant studies also recommend pepsin as a diagnostic marker (27, 28).

In this prospective study, we aimed to investigate the accuracy, usefulness, sensitivity and specificity of immunoserologic pepsin detection in the saliva. *In vitro* pepsin detection tests were compared to the 24-hour double probe pH monitoring results for each patient. The high specificity rate in our study suggested that a positive salivary pepsin test in a patient suspected of LPR can be strong evidence for the diagnosis. However the low sensitivity rate indicates uncertainty in the sample collecting frequency. In our study group, patients only collected their sputum once, when they had the worst reflux symptom. This may have caused the low sensitivity value; increasing the number of sputum samples may increase the sensitivity of the test. The sensitivity and negative predictive value is lower when compared to the relevant previously published studies. The lack of a control group and the limited numbers of patients are the limitations of our study. Nonetheless, we believe that our study will help to optimize the sample collecting procedure for further studies.

It is clear that pepsin has a key role in tissue damage in LPR and it has been well established that pepsin can cause mucosal damage, even in non-acidic reflux episodes. Therefore, pepsin can be a good alternative as a diagnostic method, particularly in patients with non-acidic reflux. The evaluation of sputum

for pepsin by immunoserology is a rapid, easy to perform and cost effective method. However, optimal frequency of sampling should be further studied in order to increase the diagnostic sensitivity for pepsin detection.

Ethics Committee Approval: Ethics committee approval was received for this study from Ankara University Ethics Committee (EC 16-534-12).

Informed Consent: Written informed consent was obtained from patients who participated in this study.

Peer-review: Externally peer-reviewed.

Author contributions: Concept - I.Y., E.O., G.K.; Design - I.Y.; Supervision - I.Y.; Resource - E.O., G.K.; Materials - E.O., G.K.; Data Collection&/orProcessing - E.O., G.K.; Analysis&/orInterpretation - E.O., G.K., I.Y.; LiteratureSearch - E.O., G.K.; Writing - E.O., G.K.; Critical Reviews - E.O., I.Y.

Conflict of Interest: No conflict of interest was declared by the authors.

Financial Disclosure: The authors declared that this study has received no financial support.

REFERENCES

1. Koufman JA. Laryngopharyngeal reflux is different from classic gastroesophageal reflux disease. *Ear Nose Throat J* 2002;81(Suppl 2):7-9.
2. Vakil N, van Zanten SV, Kahrilas P, Dent J, Jones R; Global Consensus Group. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. *Am J Gastroenterol* 2006;101:1900-20. [\[CrossRef\]](#)
3. Koufman J, Sataloff RT, Toohill R. Laryngopharyngeal reflux: consensus conference report. *J Voice* 1996;10:215-6. [\[CrossRef\]](#)
4. Belafsky PC, Postma GN, Daniel E, Koufman JA. Transnasal esophagoscopy. *Otolaryngol Head Neck Surg* 2001;125:588-9. [\[CrossRef\]](#)
5. Koufman JA. The otolaryngologic manifestations of gastroesophageal reflux disease (GERD): a clinical investigation of 225 patients using ambulatory 24-hour pH monitoring and an experimental investigation of the role of acid and pepsin in the development of laryngeal injury. *Laryngoscope* 1991;101(Suppl 53):1-78.
6. Grøntved ÅM, West F. pH monitoring in patients with benign voice disorders. *Acta Otolaryngol Suppl* 2000;120:229-31. [\[CrossRef\]](#)
7. Johnson PE, Koufman JA, Nowak LJ, Belafsky PC, Postma GN. Ambulatory 24-Hour Double-Probe pH Monitoring: The Importance of Manometry. *Laryngoscope* 2001;111:1970-5. [\[CrossRef\]](#)
8. Bulmer DM, Ali MS, Brownlee IA, Dettmar PW, Pearson JP. Laryngeal mucosa: its susceptibility to damage by acid and pepsin. *Laryngoscope* 2010;120:777-82. [\[CrossRef\]](#)
9. Sole ML, Conrad J, Bennett M, Middleton A, Hay K, Ash-worth S, Mehta DI. Pepsin and amylase in oral and tracheal secretions: a pilot study. *Am J Crit Care* 2014;23:334-8. [\[CrossRef\]](#)

10. Dinis PB, Subtil J. Helicobacter pylori and laryngopharyngeal reflux in chronic rhinosinusitis. *Otolaryngol Head Neck Surg* 2006;134:67-72. [\[CrossRef\]](#)
11. Krishnan U, Mitchell JD, Messina I, Day AS, Bohane TD. Assay of tracheal pepsin as a marker of reflux aspiration. *J Pediatr Gastroenterol Nutr* 2002;35:303-8. [\[CrossRef\]](#)
12. Belafsky PC, Postma GN, Koufman JA. Validity and reliability of the reflux symptom index (RSI). *J Voice* 2002;16:274-7. [\[CrossRef\]](#)
13. Belafsky PC, Postma GN, Koufman JA. The validity and reliability of the reflux finding score (RFS). *Laryngoscope* 2001;111:1313-7. [\[CrossRef\]](#)
14. Yuksel ES, Hong S-KS, Strugala V, Slaughter JC, Goutte M, Garrett CG, et al. Rapid Salivary Pepsin Test: Blinded Assessment of Test Performance in Gastroesophageal Reflux Disease. *Laryngoscope* 2012;122:1312-6. [\[CrossRef\]](#)
15. Knight J, Lively MO, Johnston N, Dettmar PW, Koufman JA. Sensitive pepsin immunoassay for detection of laryngopharyngeal reflux. *Laryngoscope* 2005;115:1473-8. [\[CrossRef\]](#)
16. Bollschweiler E, Feussner H, Hölscher AH, Siewert J. pH monitoring: the gold standard in detection of gastrointestinal reflux disease? *Dysphagia* 1993;8:118-21. [\[CrossRef\]](#)
17. Tseng D, Rizvi AZ, Fennerty MB, Jobe BA, Diggs BS, Sheppard BC, et al. Forty-eight-hour pH monitoring increases sensitivity in detecting abnormal esophageal acid exposure. *J Gastrointest Surg* 2005;9:1043-52. [\[CrossRef\]](#)
18. Jiang A, Liang M, Su Z, Chai L, Lei W, Wang Z, et al. Immunohistochemical detection of pepsin in laryngeal mucosa for diagnosing laryngopharyngeal reflux. *Laryngoscope* 2011;121:1426-30. [\[CrossRef\]](#)
19. Vaezi MF. Gastroesophageal reflux disease and the larynx. *J Clin Gastroenterol* 2003;36:198-203. [\[CrossRef\]](#)
20. Postma GN, Belafsky PC, Aviv JE, Koufman JA. Laryngopharyngeal reflux testing. *Ear Nose Throat J* 2002;81:14-8.
21. Wise JL, Murray JA. Utilising multichannel intraluminal impedance for diagnosing GERD: a review. *Dis Esophagus* 2007;20:83-8. [\[CrossRef\]](#)
22. Dunn BM. Structure and mechanism of the pepsin-like family of aspartic peptidases. *Chem Rev* 2002;102:4431-58. [\[CrossRef\]](#)
23. Johnston N, Dettmar PW, Bishwokarma B, Lively MO, Koufman JA. Activity/stability of human pepsin: implications for reflux attributed laryngeal disease. *Laryngoscope* 2007;117:1036-9. [\[CrossRef\]](#)
24. Samuels TL, Johnston N. Pepsin as a causal agent of inflammation during nonacidic reflux. *Otolaryngol Head Neck Surg* 2009;141:559-63. [\[CrossRef\]](#)
25. Jiang A, Liang M, Su Z, Chai L, Lei W, Wang Z, et al. Immunohistochemical detection of pepsin in laryngeal mucosa for diagnosing laryngopharyngeal reflux. *Laryngoscope* 2011;121:1426-30. [\[CrossRef\]](#)
26. Kim TH, Lee KJ, Yeo M, Kim DK, Cho SW. Pepsin detection in the sputum/saliva for the diagnosis of gastroesophageal reflux disease in patients with clinically suspected atypical gastroesophageal reflux disease symptoms. *Digestion* 2008;77:201-6. [\[CrossRef\]](#)
27. Potluri S, Friedenberg F, Parkman HP, Chang A, MacNeal R, Manus C, et al. Comparison of a salivary/sputum pepsin assay with 24-hour esophageal pH monitoring for detection of gastric reflux into the proximal esophagus, oropharynx, and lung. *Dig Dis Sci* 2003;48:1813-7. [\[CrossRef\]](#)
28. Samuels TL, Johnston N. Pepsin as a marker of extraesophageal reflux. *Ann Otol Rhinol Laryngol* 2010;119:203-8.